← Human Trials & Peer-Reviewed Studies
Plasma interleukin-6 levels, glutathione peroxidase and isoprostane in obese women before and after weight loss. Association with cardiovascular risk factors
Plain-language guide to PMID 16950753 (2006): controlled clinical trial study of Glutathione in 36 women.
Key Facts
- PMID
- 16950753
- Journal
- Hormones (Athens, Greece)
- Year
- 2006
- Study type
- Controlled Clinical Trial
- Authors
- Bougoulia M et al. (3 authors)
- DOI
- 10.14310/horm.2002.11182
What This Study Did, in Plain Language
What Was Tested
This controlled clinical trial paper looks at Glutathione.
To evaluate the levels of Interleukin-6 (IL-6), glutathione peroxidase and isoprostane in obese women and their association with markers of cardiovascular risk factors before and after weight loss.
Who Took Part
The abstract describes 36 women taking part.
The age groups tagged for this paper are adults, women only.
36 healthy obese women of reproductive age (group A: age (mean+/-SD) 35.4+/-9.2 years, Body Mass Index (BMI) 38.5+/-7 kg/m2) and 30 healthy, normal weight women (group B: age mean+/-SD 34.9+/-7.4 y., BMI 24+/-1.1 kg/m2) were included in the study.
Glucose tolerance was normal in all participating women.
How the Study Was Run
A time span of six months appears in the methods.
Il-6, glutathione peroxidase and isoprostane, C-Reactive Protein (CRP), insulin, fasting plasma glucose, HOMA-IR as well as the lipid profile were evaluated.
Body weight, BMI, Waist to Hip ratio (W/H) ratio, Waist Circumference (WC), %free fat mass and the %fat mass were also measured.
A hypo-caloric diet was prescribed for the obese women and all participants were re-examined after six months.
What Was Measured
PubMed files the paper under topics including Body Composition, Body Mass Index, C-Reactive Protein, Cardiovascular Diseases, Cholesterol, Cholesterol, HDL and Cholesterol, LDL.
What This Means in Plain Language
This is a controlled clinical trial of Glutathione in 36 women over six months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2006 (Hormones (Athens, Greece)), a journal based in Switzerland.
More context: the Glutathione compound page, all human trials.
Our Notes on the Compound
Glutathione: The body's main antioxidant.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.